參麥注射液聯合AG化療方案對晚期不可切除胰腺癌患者腫瘤標志物及免疫功能的影響

打開文本圖片集

Effects of Shenmai Injection Combined with AG Chemotherapy Regimen on Tumor Markers and Immune Function in Patients with Advanced Unresectable Pancreatic Cancer/TIAN Ning， ZHANG Shanyan， ZHOU Yuan， WANG Juan. //Medical Innovation of China， 2025， 22（12）： 017-020

[Abstract]Objective： To explorethe effects of Shenmai Injection combined with AG chemotherapy regimen on tumor markers and immune function in patients with advanced unresectable pancreatic cancer.Method： The clinical data of 80 patients with advanced unresectable pancreatic cancer admited to Tai'an Tumour Prevention and Treatment HospitalfromJanuary 2021 to June 2023 wereretrospectively analyzed，and they were divided into obsrvation group and control group according to diferent treatment regimens， with 40 cases in each group.The control group was treated with AG chemotherapy regimen，and the observation group was treated with Shenmai Injection on the basis of control group.Tumor markers，immunefunction and clinical efficacy were compared between the two groups. Result： After treatment， the levels of carcinoembryonic antigen （CEA）and carbohydrate antigen 19-9 （CA19-9）in both groups were decreased， and those in the observation group were lower than those in the control group （ P <0.05）. After treatment， the levels of CD3 + and CD4 + in both groups were increased， and those in the observation group were higher than those in the control group， the levels of CD8 in both groups were decreased， and that in the observation group was lower than that in the control group （ P <0.05）. There were no significant differences in objective response rate （ORR）， disease control rate （DCR）and mortality between the two groups （ P >0.05）. Conclusion： Shenmai Injection combined with AG chemotherapy regimen in patients with advancedunresectablepancreatic cancer can reduce thelevels of tumor markers，improve the immunefunction of patients.

[Key words] Shenmai Injection AG chemotherapy regimen Pancreatic cancer Tumor markers Immune function

First-author's address： Department of Chemotherapy， Taian Tumour Prevention and Treatmeni Hospital， Tai'an 271000， China doi： 10.3969/j.issn.1674-4985.2025.12.005

胰腺癌（pancreaticcancer，PC）是臨床惡性程度較高的腫瘤之一，預后極差，其以極高死亡率和難以治愈的特點，成為全球公共衛(wèi)生領域面臨的一大挑戰(zhàn)。（剩余5197字）